Strategies to endow cytotoxic T lymphocytes or natural killer cells with antibody activity against carcinoembryonic antigen

Tumor Biology

Volumn 25, Issue 4, 2004, Pages 208-216

  Kuroki, Masahide ^a   Kuroki, Motomu ^a   Shibaguchi, Hirotomo ^a   Badran, Adel ^a   Hachimine, Ken ^a   Zhang, Jitian ^a   Kinugasa, Tetsushi ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibody based therapy; Carcinoembryonic antigen; Cytotoxic T lymphocytes; Immunotherapy; Natural killer cell; Tumor antigen

Indexed keywords

ANTIBODY; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; HLA ANTIGEN CLASS 1; HYBRID PROTEIN;

ANTIBODY ENGINEERING; ANTIGEN BINDING; CELL SURFACE; CHIMERA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; HLA SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPHOKINE ACTIVATED KILLER CELL; MOLECULE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; TUMOR; TUMOR CELL; TUMOR ESCAPE;

EID: 9244257383     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081104     Document Type: Short Survey

References (62)

1. Groen TP: Tumor-associated antigens; in Den Otter W, Ruitenberg EJ (eds): Tumor Immunology; Mechanisms, Diagnosis, Therapy. Amsterdam, Elsevier, 1987, pp 13-27.
2. Kuroki M, Ueno A, Matsumoto H, Abe H, Li T, Imakiire T, Yamauchi Y, Uno K, Shirota K, Shibaguchi H, Kuroki M: Significance of tumor-associated antigens in the diagnosis and therapy of cancer: An overview. Anticancer Res 2002;22:4255-4264.
3. Gold P, Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122:467-481.
4. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997;57:4570-4577.
5. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA: Natural killer cell receptors: New biology and insights into the graft-versusleukemia effect. Blood 2002;100:1935-1947.
6. Algarra I, Cabrera T, Garrido F: The HLA crossroad in tumor immunology. Hum Immunol 2000;61:65-73.
7. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F: Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003;52:1-9.
8. Kuroki M, Shibaguchi H, Imakiire T, Uno K, Shirota K, Higuchi T, Shitama T, Yamada H, Hirose Y, Nagata A, Kuroki M: Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens. Anticancer Res 2003;23:4377-4381.
9. Darcy PK, Kershaw MH, Trapani JA, Smyth MJ: Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol 1998;28:1663-1672.
10. Roberts MR, Cooke KS, Tran AC, Smith KA, Lin WY, Wang M, Dull TJ, Farson D, Zsebo KM, Finer MH: Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunol 1998;161:375-384.
11. Primus FJ, Sharkey RM, Hansen HJ, Goldenberg DM: Immunoperoxidase detection of carcinoembryonic antigen. Cancer 1978;42:1540-1545.
12. Molina R, Filella X, Augé JM, Fuente R, Bover I, Rifa J, Moreno V, Canals E, Viñolas N, Marquez A, Barreiro E, Borras J, Viladiu P: Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumor Biol 2003;24:209-218
13. Molina R, Filella X, Lejarcegui JA, Pahisa J, Torné A, Rovirosa A, Mellado B, Ordi J, Puig-Tintore LM, Alicarte J, Biete A, Iglesias J: prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumor Biol 2003;24:156-164.
14. Modrak DE, Gold DV, Goldenberg DM, Blumenthal RD: Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy Tumor Biol 2003;24:32-39.
15. Nicolini A, Carpi A, Ferrari P, Pieri L: Utility of a serum tumour marker panel in the postoperative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumor Biol 2003;24:275-280.
16. Rye PD, Nustad K, Stigbrand T: Tumor marker workshops. Tumor Biol 2003;24:165-171.
17. Nap M, Mollgard K, Burtin P, Fleuren GJ: Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumor Biol 1988;9:145-153.
18. Nouwen EJ, Pollet DE, Eerdekens MW, Hendrix PG, Briers TW, De Broe ME: Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen, and cancer antigen 125 in normal and neoplastic human lung. Cancer Res 1986;46:866-876.
19. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP: Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;57:327-334.
20. Hammarström S: The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
21. Khare PD, Liao S, Kuroki M, Hirose Y, Arakawa F, Nakamura K, Tomita Y, Kuroki M: Specificaly targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retrovector displaying single chain variable fragmented (scFv) antibody to CEA and carrying inducible nitric oxide synthase (iNOS) gene. Cancer Res 2001;61:370-375.
22. Sell S: Cancer markers of the 1990s. Comparison of the new generation of markers defined by monoclonal antibodies and oncogene probes to prototypic markers. Clin Lab Med 1990;10:1-37.
23. Ikeda S, Kuroki M, Haruno M, Oikawa S, Nakazato H, Kosaki G, Matsuoka Y: Epitope mapping of the carcinoembryonic antigen with various related recombinant proteins expressed in Chinese hamster ovary cells and 25 distinct monoclonal antibodies. Mol Immunol 1992;29:229-240.
24. Beauchemin N, Draber P, Dveksler G, Gold P, Gray-Owen S, Grunert F, Hammarström S, Holmes KV, Karlsson A, Kuroki M, Lin SH, Lucka L, Najjar SM, Neumaier M, Obrink B, Shively JE, Skubitz KM, Stanners CP, Thomas P, Thompson JA, Virji M, von Kleist S, Wagener C, Watt S, Zimmermann W: Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 1999;252:243-249.
25. Kuroki M, Abe H, Imakiire T, Liao S, Uchida H, Yamauchi Y, Oikawa S, Kuroki M: Identification and comparison of residues critical for cell adhesion activities of two neutrophil CD66 antigens, CEACAM6 and CEACAM8. J Leukocyte Biol 2001;70:543-550.
26. Hammarström S, Shively JE, Paxton RJ, Beatty BG, Larsson Ghosh R, Børmer O, Buchegger F, Mach J-P, Burtin P, Seguin P, Darbouret B, Degorce F, Sertour J, Jolu JP, Fuks A, Kalthoff H, Schmiegel W, Arndt R, Kloppel G, von Kleist S, Grunert F, Schwarz K, Matsuoka Y, Kuroki M, Wagener C, Weber T, Yachi A, Imai K, Hishikawa N, Tsujisaki M: Antigenic sites in carcinoembryonic antigen. Cancer Res 1989;49:4852-4858.
27. Murakami M, Kuroki M, Arakawa F, Kuwahara M, Oikawa S, Nakazato H, Matsuoka Y: A reference of the Gold classification of monoclonal antibodies against carcinoembryonic antigen to the domain structure of the carcinoembryonic antigen molecule. Hybridoma 1995;14:19-28.
28. Bjerner J, Lebedin Y, Bellanger L, Kuroki M, Shively JE, Varaas T, Nustad K, Hammarström S, Børmer OP: Protein epitopes in carcinoembryonic antigen. Report of the ISOBM TD8 Workshop. Tumor Biol 2002;23:249-262.
29. Roitt I, Brostoff J, Male D: Immunology, ed 5, London, Mosby, 1998.
30. Buchsbaum DJ: Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res 1995;55(suppl):5729s-5732s.
31. Chester K, Pedley B, Tolner B, Violet J, Mayer A, Sharma S, Boxer G, Green A, Nagl S, Begent R: Engineering antibodies for clinical applications in cancer. Tumor Biol 2004;25:91-98.
32. Ishida I, Tomizuka K, Yoshida H, Tahara T, Takahashi N, Ohguma A, Tanaka S, Umehashi M, Maeda H, Nozaki C, Halk E, Lonberg N: Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002;4:91-102.
33. Imakiire T, Kuroki M, Shibaguchi H, Abe H, Yamauchi Y, Ueno A, Hirose Y, Yamada H, Yamashita Y, Shirakusa T, Ishida I, Kuroki M: Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen. Int J Cancer 2004;108:564-570.
34. Yamamoto T, Yoneda K, Osaki T, Yoshimura N, Akagi N: Longer local retention of adoptively transferred T-LAK cells correlates with lesser adhesion molecule expression than NK-LAK cells. Clin Exp Immunol 1995;100:13-20.
35. Parmiani G, Rivoltini L, Andreol G, Carrabba M: Cytokines in cancer therapy. Immunol Lett 2000;74:41-44.
36. Ribeiro RC, Rill D, Roberson PK, Furman WL, Pratt CB, Brenner M, Crist WM, Pui CH: Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer 1993;72:623-628.
37. Bolhuis RL, Sturm E, Braakman E: T cell targeting in cancer therapy. Cancer Immunol Immunother 1991;34:1-8.
38. Kuwahara M, Kuroki M, Arakawa F, Senba T, Matsuoka Y, Hideshima T, Yamashita Y, Kanda H: A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. Anticancer Res 1996;16:2661-2667.
39. Baba M, Hideshima T, Yamashita Y, Shirakusa T: Potentiation of cytotoxicity against a CEA-positive cell line by the bispecific antibody OH1 using LAK cells from cancer-bearing patients. Oncol Rep 1998;5:1141-1146.
40. Kufer P, Mack M, Gruber R, Lutterbuse, R, Zettl F, Riethmuller G: Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother 1997;45:193-197.
41. Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Qinghua L, Wolf J, Diehl V, Cochet O, Winter G, Bohlen H: Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 1999;59:2909-2916.
42. Asano R, Kudo T, Nishimura, Y, Makabe K, Hayashi H, Suzuki M, Tsumoto K, Kumagai I: Efficient construction of a diabody using a refolding system: Anti-carcinoembryonic antigen recombinant antibody fragment. J Biochem (Tokyo) 2002;132:903-909.
43. Blanco B, Holliger P, Vile RG, Alvarez-Vallina L: Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumorspecific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 2003;171:1070-1077.
44. Penichet ML, Morrison SL: Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 2001;248:91-101.
45. Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E, Primus FJ: Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 2000;60:4475-4484.
46. Liao S, Khare PD, Arakawa F, Kuroki M, Hirose Y, Fujimura S, Tomita Y, Kuroki M: Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein. Anticancer Res 2001;1673-1680.
47. Kalland T, Dohlsten M, Abrahmsen L, Hedlund G, Bjork P, Lando PA, Sundstedt A, Akerblom E, Lind P: Targeting of superantigens. Cell Biophys 1993;22:147-164.
48. Ueno A, Arakawa F, Abe H, Matsumoto H, Kudo T, Asano R, Tsumoto K, Kumagai I, Kuroki M, Kuroki M: T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Anticancer Res 2002;22:769-776.
49. Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y: Expression of chimeric receptor composed of immunoglobulin- derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1987;149:960-968.
50. Schirrmann T, Pecher G: Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther 2002;9:390-398.
51. Patel SD, Moskalenko M, Smith D, Maske B, Finer MH, McArthur JG: Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther 1999;6:412-419.
52. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK: Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002;169:5780-5786.
53. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H: Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001;167:6123-6131.
54. Gilham DE, O'Neil A, Hughes C, Guest RD, Kirillova N, Lehane M, Hawkins RE: Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3 zetabased chimeric immune receptors. J Immunother 2002;25:139-151.
55. Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ, Junghans RP: Bypassing immunization: Optimized design of 'designer T cells' against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999;5:3928-3941.
56. Arakawa F, Shibaguchi H, Xu Z, Kuroki M: Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity. Anticancer Res 2002;22:4285-4290.
57. Sheen AJ, Irlam J, Kirillova N, Guest RD, Sherlock DJ, Hawkins RE, Gilham DE: Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum 2003;46:793-804.
58. Robert B, Guillaume P, Luescher I, Romero P, Mach JP: Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur J Immunol 2000;30:3165-3170.
59. Robert B, Guillaume P, Luescher I, Doucey MA, Cerottini JC, Romero P, Mach J-P: Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class Iviral peptide conjugated to antibody fragments. Cancer Immun 2001;1:2.
60. Lev A, Novak H, Segal D, Reiter Y: Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes. J Immunol 2002;169:2988-2996.
61. Donda A, Cesson V, Mach J-P, Corradin G, Primus FF, Robert B: In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts. Cancer Immun 2003;3:11.
62. Segal DM, Dower SK, Titus JA: The role of non-immune IgG in controlling IgG-mediated effector functions. Mol Immunol 1983;20:1177-1189.